Corteria Pharma is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological diseases. The company's lead product candidate is targeting Multiple Sclerosis (MS) with a potential best-in-class profile.

Philip Janiak

Marie-Laure Ozoux

Corteria Pharma

Biotech 365 provides business support services for biotech companies, focusing on fundraising, licensing, and connecting companies with healthcare investors through their global network.

Biotech 365

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Neovacs S.A.

Development of transformative therapies for the treatment of worsening and acute decompensated heart failure

Metric
Company Name	Corteria Pharma	Biotech 365	Neovacs S.A.
Symbol			ALNEV
MSH ID	COM:CORTERIAPHARMA	COM:BIOTECH-365	COM:NEOVACS
Market	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Financial Services & Finance	Healthcare
Industry	Biopharmaceuticals	Biotechnology Business Services	Biotechnology
Country	FR	FR	FR
Stage			Post-IPO Debt
Employee Count	10		22
Website	corteriapharma.com	biotech-365.com	neovacs.com
LinkedIn	corteria-pharmaceuticals		neovacs
Founders

Metric
Market Cap		52.99K
Enterprise Value
Monthly Web Traffic	68
Web Traffic Growth	-0.57
Valuation
Raised Capital		4.77M

Metric
Revenue			563.41K
Revenue (LTM)
Revenue (NTM)
Gross Profit			-7.13M
EBITDA			-7.12M
Operating Income			-7.30M
Net Income			-9.24M
EPS			-0.00
Diluted EPS			-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			-9.71
Operating Profit Margin			-12.95
EBITDA Margin			-12.64
Net Profit Margin			-16.39
Return on Equity			-0.12
Return on Assets			-0.11
Return on Capital Employed			-0.14

COM:CORTERIAPHARMA

Corteria Pharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			5.78
EV Multiple			-0.04

Metric
Days Sales Outstanding
Days Payables Outstanding			1.22K
Days Inventory Outstanding
Operating Cycle			11.67K
Cash Conversion Cycle			11.39K
Asset Turnover			0.01

Metric
Operating Cash Flow			-2.02M
Free Cash Flow			-2.24M
Cash Flow to Debt			-1.47
Operating Cash Flow/Sales			-3.59
Free Cash Flow Yield			-0.00

Metric
Cash & Equivalents			936.97K
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization			0.06
Debt to Assets			0.02
Current Ratio			2.32
Quick Ratio			1.34

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue